Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor. (October 2020) - Janku, F.; Sherman, E.J.; Parikh, A.R.; Feun, L.G.; Tsai, F.; Allen, E.; Zhang, C.; Severson, P.; Inokuchi, K.; Walling, J.; Averbuch, S.; Tarcic, G.; et al.